T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects”
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
T cells with high BCL-2 expression induced by venetoclax impact anti-leukemic immunity “graft-versus-leukemia effects” ; volume:14 ; number:1 ; day:14 ; month:5 ; year:2024 ; pages:1-5 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (14.5.2024), 1-5, 12.2024
- Creator
-
Nagasaki, Joji
Nishimoto, Mitsutaka
Koh, Hideo
Okamura, Hiroshi
Nakamae, Mika
Sakatoku, Kazuki
Ido, Kentaro
Kuno, Masatomo
Makuuchi, Yosuke
Takakuwa, Teruhito
Nakashima, Yasuhiro
Hino, Masayuki
Nakamae, Hirohisa
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01064-0
- URN
-
urn:nbn:de:101:1-2407240800353.548285887220
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nagasaki, Joji
- Nishimoto, Mitsutaka
- Koh, Hideo
- Okamura, Hiroshi
- Nakamae, Mika
- Sakatoku, Kazuki
- Ido, Kentaro
- Kuno, Masatomo
- Makuuchi, Yosuke
- Takakuwa, Teruhito
- Nakashima, Yasuhiro
- Hino, Masayuki
- Nakamae, Hirohisa
- SpringerLink (Online service)
Other Objects (12)
BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
Metabolic instruction of the graft-versus-leukemia immunity
Der BCL-2 Inhibitor ABT-199/Venetoclax transaktiviert NOXA und wirkt mit Proteasom-Inhibition bei der Zelltod-Induktion synergistisch
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia
b-cl
b-cl
b-cl
BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
Metabolic instruction of the graft-versus-leukemia immunity
Der BCL-2 Inhibitor ABT-199/Venetoclax transaktiviert NOXA und wirkt mit Proteasom-Inhibition bei der Zelltod-Induktion synergistisch
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia
b-cl
b-cl
b-cl
BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)
Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib‐resistant non‐nodal leukemic mantle cell lymphoma
Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia
Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
Metabolic instruction of the graft-versus-leukemia immunity
Der BCL-2 Inhibitor ABT-199/Venetoclax transaktiviert NOXA und wirkt mit Proteasom-Inhibition bei der Zelltod-Induktion synergistisch
NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia
b-cl
b-cl